It’s not so straightforward when it comes to rapamycin and bone health:
Claude AI said the following:
There’s a real and fairly substantial evidence base, spanning animal mechanistic work up through human trial data — though there’s an important wrinkle in the human dosing story that complicates the simple “rapamycin = good for bone” framing.
Animal/mechanistic level:
Rapamycin given to aged rats increased trabecular bone mineralization alongside declining osteoclast numbers and elevated osteocyte autophagy. In a mouse model of iron-accumulation-driven osteoporosis, rapamycin attenuated osteogenesis and angiogenesis pathways to improve bone mass, and mTOR inhibition in vivo restored both osteogenesis and angiogenesis. Separately, rapamycin reduced bone cell death and increased bone mineral density, volume, and thickness in a mouse model of oxidative-stress-induced bone aging, working through improved mitophagy. ScienceDirectNMN
Human evidence (the more interesting part):
A 2022 systematic review (Lin et al., Aging Clinical and Experimental Research) pulled together the human trial data specifically. Key findings across five studies:
- In renal transplant patients, rapamycin lowered serum osteocalcin and urinary N-telopeptide (bone resorption markers) compared to cyclosporine.
- Another transplant study found rapamycin significantly lowered TRAP-5b and sRANKL (osteoclast activity/differentiation markers) versus calcineurin-inhibitor therapy, with in vitro confirmation that rapamycin suppressed osteoclast maturation.
- In postmenopausal breast cancer patients, everolimus (a rapalogue) significantly reduced bone turnover markers (BSAP, P1NP, CTX) compared to control, an effect the authors attributed to suppressed osteoclastogenesis.
The review’s overall conclusion: most human studies show rapamycin and rapalogues positively regulate bone turnover via reduced osteoclastogenesis. springer
Where it gets messier — the dosage-dependence problem:
A separate mechanistic paper found something that cuts against the clean story: rapamycin treatment at low but clinically relevant doses actually exacerbated osteoclast differentiation and bone resorption, leading to bone loss, revealing biphasic, dosage-dependent effects on bone. So the direction of effect isn’t fixed — it depends on dose, and possibly on timing relative to bone remodeling cycles. nih
Caveats worth sitting with, given your own evidence-tiering standards:
- Most of the positive human data comes from transplant and cancer populations on chronic, continuous dosing for immunosuppression — not healthy adults on intermittent longevity protocols like yours. The review itself flags this: the clinical context doesn’t correspond merely to aging, and confounders like renal osteodystrophy, post-transplant hyperparathyroidism, and aromatase-inhibitor-driven bone loss were highly prevalent in these cohorts. springer
- None of the human bone studies used actual bone density (DXA) as the outcome — they used serum/urine turnover markers, which are a step removed from real structural bone health.
- Nobody’s studied intermittent dosing protocols specifically for bone effects in otherwise-healthy people — the biphasic/dose-dependent finding means your specific protocol’s effect on bone is genuinely unmapped territory rather than something you can safely extrapolate from either the transplant data or the animal data.
Net effect: the mechanistic and human-marker evidence leans toward rapamycin reducing bone resorption (bone-protective), but the sclerostin-increase finding you raised earlier and the dose-dependent bone-loss finding here show the system isn’t monotonic — it’s a case where the same drug can look protective or harmful depending on dose, duration, and context, and the honest answer is that nobody has resolved which end of that spectrum intermittent low-dose human protocols land on.